Dupilumab Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe/ Prefilled Pen)

Available Strengths: 200 mg/1.14 mL, 300 mg/2 mL

Reference Brands: Dupixent (USA)

Category: Immune Disorder

Dupilumab is a fully human monoclonal antibody that targets the interleukin-4 receptor alpha (IL-4Rα), blocking the signaling of IL-4 and IL-13, key cytokines involved in type 2 inflammation. By modulating this immune pathway, Dupilumab helps control chronic immune-mediated conditions. Dupilumab is available in injection (prefilled syringe/ Prefilled Pen) and strengths such as 200 mg/1.14 mL, 300 mg/2 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Dupilumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Dupilumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Dupilumab, marketed under the brand name Dupixent, is a fully human monoclonal antibody that targets the interleukin-4 receptor alpha (IL-4Rα), thereby blocking IL-4 and IL-13 receptor signaling. These cytokines are central drivers of type 2 inflammation, which plays a key role in several chronic allergic and inflammatory conditions.

Dupilumab is approved for the treatment of moderate-to-severe atopic dermatitis (eczema), asthma, and chronic rhinosinusitis with nasal polyps. It is also indicated for other type 2 inflammatory disorders, including eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease (COPD). By inhibiting IL-4 and IL-13 signaling, dupilumab reduces inflammation, alleviates symptoms, improves skin and respiratory function, and enhances quality of life for patients with these conditions.

The medication is administered as a subcutaneous injection, typically every two weeks, with dosing adjusted based on the patient’s condition and weight. Clinical studies have demonstrated significant improvement in disease severity, symptom control, and long-term safety, making dupilumab an important therapeutic option for patients with type 2 inflammatory diseases.